INTUITIVE SURGICAL INC ISRG

Intuitive Surgical’s strongest current evidence is the filed operating quarter: revenue from contracts with customers, excluding assessed tax, was $2.77B in the 10-Q for the period ending 2026-03-31, with net income attributable to the parent of $821.5M, operating income of $855.3M, diluted EPS of $2.28 and net cash provided by operating activities of $911.9M. That is the centre of the daily story, because it is filed financial substance rather than loose market weather.

The company is an operating business tied to minimally invasive care. The supplied 10-Q says Intuitive is committed to advancing minimally invasive care through a comprehensive ecosystem of products and services, while the official issuer website is supplied as an official source page. That product rail matters because the reported revenue, inventory, R&D and leasing details attach to a real healthcare equipment and services business, not a generic equity wrapper.

The balance sheet in the latest parsed filing is also material. Assets were $20.11B at 2026-03-31, liabilities were $2.51B, stockholders' equity attributable to the parent was $17.47B, and cash and cash equivalents at carrying value were $2.01B. The same 10-Q reports research and development expense of $361.9M, inventory, net, of $1.95B, an increase in inventories of $266.6M, and diluted weighted average shares outstanding of 359.8M. The product and revenue detail supplied by the scout includes sales-type lease revenue of $32.7 and $26.5, and cost of revenue, product, of $29.3 and $30.2, but the rail as provided does not specify the comparative period labels beyond the filing extract.

No approved chart route is supplied in this evidence pack, so there is no defensible chart commentary, level, trend line, support area, resistance area or candle read to report. The market mechanism here is therefore source-led: official SEC filings, the issuer website, recent 8-K documents, Form 4 filings, Form 144 notices, SEC submissions JSON and SEC companyfacts JSON. The daily file should be read as a filing-backed operating update, not a technical-market note.

What changed in the current public rail is the concentration of recent official filings: SEC EDGAR lists Form 4 filings dated 2026-06-12 and 2026-06-10, Form 144 notices dated 2026-06-10 and 2026-06-08, an 8-K dated 2026-05-28 with a press release issued by Intuitive Surgical, Inc., an 8-K dated 2026-05-04, and the 10-Q dated 2026-04-22 for the quarter ending 2026-03-31. The evidence does not supply analyst commentary, price action, guidance, a new approval, or a new product launch, so those claims stay out of the report.

The clean tension is between a highly profitable, cash-generative care-technology business and the source limits of today’s pack. The official documents establish revenue, income, cash flow, R&D, inventory, balance sheet strength and recent insider-related filing activity. They do not establish a fresh commercial acceleration, pricing change, regulatory win, competitive shift, or market valuation argument.